Entasis Therapeutics Holdings Inc (ETTX) Stock Analyst Ratings
USA - NASDAQ:ETTX - US2936141033 - Common Stock
2.19
-0.01 (-0.45%)
ChartMill assigns a Buy % Consensus number of 48% to ETTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.04. This target is -6.85% below the current price.
ETTX was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about ETTX.
In the previous month the buy percentage consensus was at a similar level.
ETTX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-05-06 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-03-08 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-03-04 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-10-20 | BMO Capital | Maintains | Outperform |
| 2021-10-19 | HC Wainwright & Co. | Maintains | Buy |
Entasis Therapeutics Holdings Inc / ETTX FAQ
What is the average price target for Entasis Therapeutics Holdings Inc (ETTX) stock?
8 analysts have analysed ETTX and the average price target is 2.04 null. This implies a price decrease of -6.85% is expected in the next year compared to the current price of 2.19.
What is the consensus rating for Entasis Therapeutics Holdings Inc (ETTX) stock?
The consensus rating for Entasis Therapeutics Holdings Inc (ETTX) is 47.5 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts have analysed Entasis Therapeutics Holdings Inc (ETTX)?
The number of analysts covering Entasis Therapeutics Holdings Inc (ETTX) is 8.